Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Understanding Major Depressive Disorder: Its Impact and Treatment Options

(BPT) - This article was sponsored and developed by Neurocrine Biosciences, Inc.

Major depression is one of the most common mental health conditions in the United States, impacting both adolescents and adults.1 It can affect all aspects of life, including relationships with family, friends and community.

Major depressive disorder (MDD) is depression that persists nearly daily for at least two weeks, with episodes lasting six months or even years if left untreated. While difficult life events can trigger depression, MDD has many causes, including social, psychological, biological, and environmental factors.2,3 According to the World Health Organization, people living with MDD may experience poor concentration, excessive guilt or low self-worth, hopelessness about the future, thoughts of death or suicide, disrupted sleep, changes in appetite or weight and extreme tiredness or low energy.2

In the U.S., more than 21 million people live with MDD.

Treatment Options
There are several Food and Drug Administration-approved treatment options for people living with MDD. Treatment usually includes a combination of antidepressants and psychotherapy. Unfortunately, the current treatment options do not work for everyone. About one-third of people living with MDD do not respond to available antidepressant medications.1,4

Many people do not see an improvement or a significant reduction in symptoms after trying two or more different medications for MDD. Approximately 86 percent of those trying a third oral antidepressant still do not achieve lasting relief from symptoms, also known as remission.5

New treatment options are needed for the many people living with MDD who do not respond to current treatments.

Ongoing Research
Clinical studies evaluate the safety and effectiveness of investigational therapies and can potentially lead to new treatment options for patients. There are ongoing clinical studies exploring potential treatments for MDD, including what is referred to as an adjunctive treatment that could be used together with an existing MDD treatment.

Neurocrine Biosciences is conducting a Phase 3 study to assess the efficacy and safety of investigational osavampator (formerly NBI-1065845) as an adjunctive treatment for people with MDD. The clinical study is currently enrolling adults aged 18 and older who have the primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder and who are currently taking oral antidepressant medications and have not responded adequately.

Maurizio Fava, M.D., Chair, Mass General Brigham Academic Medical Center, Department of Psychiatry explains, "Major depressive disorder is a condition that has a profound effect on patients and their families. The great majority of patients suffering from major depressive disorder do not achieve a sustained remission of their condition, and the options for next-step strategies to help them are quite limited. As a field, we need new augmentation strategies to enhance the efficacy of standard antidepressants."

If you or someone you know may be interested in learning more about this clinical study, please visit this website for additional information.

REFERENCES

  1. Major depression. National Institute of Mental Health. Updated July 2023. Accessed January 29, 2025. https://nimh.nih.gov/health/statistics/major-depression
  2. Depressive disorder (depression). World Health Organization. Updated March 31, 2023. Accessed January 29, 2025. https://www.who.int/news-room/fact-sheets/detail/depression
  3. Bains N, Abdijadid S. Major depressive order. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing; 2023. Updated April 10, 2023. Accessed January 25, 2025. https://www.ncbi.nlm.nih.gov/books/NBK559078
  4. Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. doi:10.4088/JCP.20m13699
  5. Sakurai H, Suzuki T, Yoshimura K, Mimura M, Uchida H. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Psychopharmacology (Berl). 2017;234(16):2453-2461. doi:10.1007/s00213-017-4634-5

© 2025 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-NBI-US-0138 4/2025

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.